Myeloma Research NewsTrial to Explore Benefits of Exercise Before Autologous Stem Cell Transplant in Myeloma PatientsMyeloma Research NewsIt has been suggested that exercise before this treatment — prehabilitation exercise — not only boosts the recover… Continue reading
Genetic Literacy ProjectGene editing in agriculture & food: Accelerating the second green revolutionCleantech GroupPressure on global resources to support our food system is growing, and even outpacing ability to meet demand. Genetic engineering is… Continue reading
Madison.com |
Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today
Madison.com Shares of synthetic biology pioneer Amyris (NASDAQ: AMRS) soared over 28% today after the company announced fourth-quarter and full-year 2017 earnings. The company reported 113% revenue growth in 2017 compared to 2016, guided for up to $195 million in … Noteworthy Stocks to Watch for: Amyris, Inc. (NASDAQ:AMRS), Guess’, Inc. (NYSE:GES)The Oracle Examiner Amyris (AMRS) Upgraded at Zacks Investment Researchregistrarjournal.com |
Madison.com |
Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today
Madison.com Shares of synthetic biology pioneer Amyris (NASDAQ: AMRS) soared over 28% today after the company announced fourth-quarter and full-year 2017 earnings. The company reported 113% revenue growth in 2017 compared to 2016, guided for up to $195 million in … Noteworthy Stocks to Watch for: Amyris, Inc. (NASDAQ:AMRS), Guess’, Inc. (NYSE:GES)The Oracle Examiner Amyris (AMRS) Upgraded at Zacks Investment Researchregistrarjournal.com |
Nasdaq |
Here’s an ETF to Invest in Immunotherapy–the Game Changing Cancer Treatment
Nasdaq In this episode of ETF Spotlight, I talked with Brad Loncar, CEO of Loncar Investments, who created the Loncar Cancer Immunotherapy Index, the underlying benchmark for the Loncar Cancer Immunotherapy ETF CNCR . Immunotherapy is often called a game … |
registrarjournal.com |
Here’s Why Amyris Stock Jumped as Much as 28.5% Higher Today
Fox Business Shares of synthetic biology pioneer Amyris (NASDAQ: AMRS) soared over 28% today after the company announced fourth-quarter and full-year 2017 earnings. The company reported 113% revenue growth in 2017 compared to 2016, guided for up to $195 million in … Noteworthy Stocks to Watch for: Amyris, Inc. (NASDAQ:AMRS), Guess’, Inc. (NYSE:GES)The Oracle Examiner Amyris (AMRS) Upgraded at Zacks Investment Researchregistrarjournal.com The Amyris (AMRS) Posts Earnings Results, Beats Expectations By $0.54 EPSBangaloreWeekly |